New approaches to the study of sepsis

EMBO Molecular Medicine

Volumn 4, Issue 12, 2012, Pages 1234-1243

  Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Complement; Interventions; Mediators; Sepsis

Indexed keywords

CD18 ANTIGEN; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RAF PROTEIN; RAS PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; APOPTOSIS; BACTERIAL TRANSLOCATION; BINDING SITE; CLINICAL TRIAL (TOPIC); CONTINUOUS HEMOFILTRATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE MODEL; ENDOTHELIUM CELL; ENDOTOXEMIA; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE INFECTION; MACROPHAGE; MONOCYTE; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; REVIEW; SEPSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INFLAMMATION; MULTIPLE ORGAN FAILURE; RECEPTOR, ANAPHYLATOXIN C5A; SEPSIS;

EID: 84872407093     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201375     Document Type: Review

References (80)

1. Adrie C, Azoulay E, Francais A, Clec'h C, Darques L, Schwebel C, Nakache D, Jamali S, Goldgran-Toledano D, Garrouste-Orgeas M, et al (2007) Influence of gender on the outcome of severe sepsis: a reappraisal. Chest 132: 1786-1793.
2. Angus DC (2010) The lingering consequences of sepsis: a hidden public health disaster? JAMA 304: 1833-1834.
3. Angus DC (2011) The search for effective therapy for sepsis: back to the drawing board? JAMA 306: 2614-2615.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
5. Bagshaw SM (2008) Short- and long-term survival after acute kidney injury. Nephrol Dial Transplant 23: 2126-2128.
6. Banks WA (2008) The blood-brain barrier: connecting the gut and the brain. Regul Pept 149: 11-14.
7. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871.
8. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81: 1-5.
9. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD II, Kreisel D, Krupnick AS, et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306: 2594-2605.
10. Buras JA, Holzmann B, Sitkovsky M (2005) Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4: 854-865.
11. Chen GY, Nunez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10: 826-837.
12. Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, Lee T, Baribault H, Tian H, Yeh WC (2007) C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446: 203-207.
13. Choudhry MA, Bland KI, Chaudry IH (2006) Gender and susceptibility to sepsis following trauma. Endocr Metab Immune Disord Drug Targets 6: 127-135.
14. Clark JA, Coopersmith CM (2007) Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 28: 384-393.
15. Cole L, Bellomo R, Davenport P, Tipping P, Uchino S, Tetta C, Ronco C (2002) The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 17: 1950-1956.
16. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301: 2445-2452.
17. Deitch EA (1998) Animal models of sepsis and shock: a review and lessons learned. Shock 9: 1-11.
18. Deitch EA (2002) Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings? Surgery 131: 241-244.
19. Dejager L, Pinheiro I, Dejonckheere E, Libert C (2011) Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 19: 198-208.
20. Devoy A, Bunton-Stasyshyn RK, Tybulewicz VL, Smith AJ, Fisher EM (2012) Genomically humanized mice: technologies and promises. Nat Rev Genet 13: 14-20.
21. Doi K, Leelahavanichkul A, Yuen PS, Star RA (2009) Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 119: 2868-2878.
22. Dyson A, Singer M (2009) Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 37: S30-S37.
23. Eachempati SR, Hydo L, Barie PS (1999) Gender-based differences in outcome in patients with sepsis. Arch Surg 134: 1342-1347.
24. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG (1992) Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148: 2724-2730.
25. Fang FC (2004) Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2: 820-832.
26. Fink MP (2008) Animal models of sepsis and its complications. Kidney Int 74: 991-993.
27. Fink MP, Heard SO (1990) Laboratory models of sepsis and septic shock. J Surg Res 49: 186-196.
28. Fry TJ, Mackall CL (2005) The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 174: 6571-6576.
29. Geiselhart LA, Humphries CA, Gregorio TA, Mou S, Subleski J, Komschlies KL (2001) IL-7 administration alters the CD4: CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J Immunol 166: 3019-3027.
30. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, Gerard C (2005) An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 280: 39677-39680.
31. Gertsch J, Viveros-Paredes JM, Taylor P (2011) Plant immunostimulants - scientific paradigm or myth? J Ethnopharmacol 136: 385-391.
32. Guo RF, Ward PA (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821-852.
33. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G (2008) Clinical review: critical illness polyneuropathy and myopathy. Crit Care 12: 238-246.
34. Hiromatsu T, Yajima T, Matsuguchi T, Nishimura H, Wajjwalku W, Arai T, Nimura Y, Yoshikai Y (2003) Overexpression of interleukin-15 protects against Escherichia coli-induced shock accompanied by inhibition of tumor necrosis factor-alpha-induced apoptosis. J Infect Dis 187: 1442-1451.
35. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
36. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 96: 14541-14546.
37. Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Guo RF, Padgaonkar VA, Younkin EM, Laudes IJ, Riedemann NC, Younger JG, et al (2001) Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 15: 568-570.
38. Laudes IJ, Guo RF, Riedemann NC, Speyer C, Craig R, Sarma JV, Ward PA (2004) Disturbed homeostasis of lung intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 during sepsis. Am J Pathol 164: 1435-1445.
39. Marshall JC (2008) Sepsis: rethinking the approach to clinical research. J Leukoc Biol 83: 471-482.
40. Monk PN, Scola AM, Madala P, Fairlie DP (2007) Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 152: 429-448.
41. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H (2008) Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 14: 257-263.
42. O'Reilly T, Zak O (1992) Enhancement of the effectiveness of antimicrobial therapy by muramyl peptide immunomodulators. Clin Infect Dis 14: 1100-1109.
43. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB, Brodbeck RM, Krause JE, Choe HR, Gerard NP, et al (2003) C5L2, a nonsignaling C5A binding protein. Biochemistry 42: 9406-9415.
44. Opal SM (2002) The clinical relevance of endotoxin in human sepsis: a critical analysis. J Endotoxin Res 8: 473-476.
45. Oppenheim JJ, Tewary P, de la Rosa G, Yang D (2007) Alarmins initiate host defense. Adv Exp Med Biol 601: 185-194.
46. Pardo M, Budick-Harmelin N, Tirosh B, Tirosh O (2008) Antioxidant defense in hepatic ischemia-reperfusion injury is regulated by damage-associated molecular pattern signal molecules. Free Radic Biol Med 45: 1073-1083.
47. Ranzani OT, Ferrer M, Esperatti M, Giunta V, Bassi GL, Carvalho CR, Torres A (2012) Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. Crit Care Med 40: 2552-2561.
48. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G (1995) Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4: 89-95.
49. Remick DG, Ward PA (2005) Evaluation of endotoxin models for the study of sepsis. Shock 24 (Suppl 1): 7-11.
50. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, Zetoune FS, Gerard NP, Cianflone K, Kohl J, et al (2008) Functional roles for C5a receptors in sepsis. Nat Med 14: 551-557.
51. Rittirsch D, Hoesel LM, Ward PA (2007) The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81: 137-143.
52. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA (2009) Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4: 31-36.
53. Russell JA (2006) Management of sepsis. N Engl J Med 355: 1699-1713.
54. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F (1998) Gender differences in human sepsis. Arch Surg 133: 1200-1205.
55. Schultz MJ, van der Poll T (2002) Animal and human models for sepsis. Ann Med 34: 573-581.
56. Schumer W (1976) Steroids in the treatment of clinical septic shock. Ann Surg 184: 333-341.
57. Shimizu T, Endo Y, Tsuchihashi H, Akabori H, Yamamoto H, Tani T (2006) Endotoxin apheresis for sepsis. Transfus Apher Sci 35: 271-282.
58. Sieberth HG, Kierdorf HP (1999) Is cytokine removal by continuous hemofiltration feasible? Kidney Int 72 (Suppl): S79-S83.
59. Speyer CL, Gao H, Rancilio NJ, Neff TA, Huffnagle GB, Sarma JV, Ward PA (2004) Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 165: 2187-2196.
60. Speyer CL, Ward PA (2011) Role of endothelial chemokines and their receptors during inflammation. J Invest Surg 24: 18-27.
61. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, et al (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205: 1701-1714.
62. Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, Collins JA, Raffin TA (1986) Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 77: 1812-1816.
63. Tang CH, Middleton PM, Savkin AV, Chan GS, Bishop S, Lovell NH (2010) Non-invasive classification of severe sepsis and systemic inflammatory response syndrome using a nonlinear support vector machine: a preliminary study. Physiol Meas 31: 775-793.
64. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664.
65. Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, et al (2010) IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 184: 3768-3779.
66. Vetvicka V (2011) Glucan-immunostimulant, adjuvant, potential drug. World J Clin Oncol 2: 115-119.
67. Vincent JL, Sun Q, Dubois MJ (2002) Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34: 1084-1093.
68. Ward PA (2004) The dark side of C5a in sepsis. Nat Rev Immunol 4: 133-142.
69. Ward PA (2010) The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2: 439-445.
70. Webster NR, Galley HF (2009) Immunomodulation in the critically ill. Br J Anaesth 103: 70-81.
71. Wichmann MW, Inthorn D, Andress HJ, Schildberg FW (2000) Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 26: 167-172.
72. Winchester JF, Kellum JA, Ronco C, Brady JA, Quartararo PJ, Salsberg JA, Levin NW (2003) Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif 21: 79-84.
73. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE (2010) Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38: 1276-1283.
74. Woodruff TM, Nandakumar KS, Tedesco F (2011) Inhibiting the C5-C5a receptor axis. Mol Immunol 48: 1631-1642.
75. Wrann CD, Winter SW, Barkhausen T, Hildebrand F, Krettek C, Riedemann NC (2007) Distinct involvement of p38-, ERK1/2 and PKC signaling pathways in C5a-mediated priming of oxidative burst in phagocytic cells. Cell Immunol 245: 63-69.
76. Wu R, Xu Y, Song X, Meng X (2002) Gene expression of adhesion molecules in pulmonary and hepatic microvascular endothelial cells during sepsis. Chin J Traumatol 5: 146-150.
77. Yachamaneni S, Yushin G, Yeon SH, Gogotsi Y, Howell C, Sandeman S, Phillips G, Mikhalovsky S (2010) Mesoporous carbide-derived carbon for cytokine removal from blood plasma. Biomaterials 31: 4789-4794.
78. Yang D, de la Rosa G, Tewary P, Oppenheim JJ (2009) Alarmins link neutrophils and dendritic cells. Trends Immunol 30: 531-537.
79. Zanotti-Cavazzoni SL, Goldfarb RD (2009) Animal models of sepsis. Crit Care Clin 25: 703-719, vii-viii.
80. Zipfel C, Robatzek S (2010) Pathogen-associated molecular pattern-triggered immunity: veni, vidi...? Plant Physiol 154: 551-554.